Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Conditioning Regimens

High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia

Bone Marrow Transplantation volume 35, pages 653–661 (2005)Cite this article

Summary:

To reduce relapse following allogeneic transplantation for AML, intensification of high-dose busulfan/cyclophosphamide using additional agents has been investigated but with few reported comparisons. We compared an intensified regimen of etoposide (60 mg/kg), busulphan (14 mg/kg), and cyclophosphamide (120 mg/kg) (BuCyVP) with BuCy2 in 237 AML patients. No significant difference in overall outcome was observed following BuCyVP (n=127) or BuCy2 (n=110). The 5-year survival was 27.3 and 30.1% following BuCyVP and BuCy2, respectively (P=0.48). Similarly, the 5-year cumulative incidence of relapse (CIR) was 28.3 and 34.8% with BuCyVP and BuCy2 (P=0.45), respectively. On multivariable analysis, patients transplanted in CR1 (P=0.002) and from related donors (P=0.013) had longer survival, while disease status at transplant was the only factor predicting CIR (P=0.002). In a separate analysis of CR1 patients (n=56), there was no significant difference in survival (P=0.37) or CIR (P=0.87) between the two regimens. However, for more advanced disease, there was a trend towards less relapse with BuCyVP (P=0.08), which was balanced by a higher cumulative incidence of transplant-related deaths (P=0.03) compared to BuCy2, resulting in similar survival. Overall, our results do not support the use of the more intensive BuCyVP regimen over BuCy2 in either early or more advanced disease AML patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Santos GW, Tutschka PJ, Brookmeyer R et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 1983; 309: 1347–1353.

    Article  CAS  PubMed  Google Scholar 

  2. Tutschka PJ, Copelan EA, Klein JP . Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987; 70: 1382–1388.

    CAS  PubMed  Google Scholar 

  3. Copelan EA, Biggs JC, Thompson JM et al. Treatment for acute myelocytic leukemia with allogeneic bone marrow transplantation following preparation with BuCy2. Blood 1991; 78: 838–843.

    CAS  PubMed  Google Scholar 

  4. Tutschka PJ . Use of busulfan containing chemotherapy for conditioning patients with leukemia for bone marrow allografting. Bone Marrow Transplant 1993; 12 (Suppl. 1): 34–36.

    PubMed  Google Scholar 

  5. Devergie A, Blaise D, Attal M et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan–cytoxan vs cytoxan–total body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (SFGM). Blood 1995; 85: 2263–2268.

    CAS  PubMed  Google Scholar 

  6. Blume KG, Kopecky KJ, Henslee-Downey JP et al. A prospective randomized comparison of total body irradiation–etoposide vs busulfan–cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group study. Blood 1993; 81: 2187–2193.

    CAS  PubMed  Google Scholar 

  7. Clift RA, Buckner CD, Thomas ED et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994; 84: 2036–2043.

    CAS  PubMed  Google Scholar 

  8. Geller RB, Saral R, Piantadosi S et al. Allogeneic bone marrow transplantation after high-dose busulfan and cyclophosphamide in patients with acute nonlymphocytic leukemia. Blood 1989; 73: 2209–2218.

    CAS  PubMed  Google Scholar 

  9. Lynch MH, Petersen FB, Appelbaum FR et al. Phase II study of busulfan, cyclophosphamide and fractionated total body irradiation as a preparatory regimen for allogeneic bone marrow transplantation in patients with advanced myeloid malignancies. Bone Marrow Transplant 1995; 15: 59–64.

    PubMed  Google Scholar 

  10. Hirabayashi N, Goto S, Ishii M et al. Busulfan, cyclophosphamide and total body irradiation as conditioning for allogeneic bone marrow transplantation for acute and chronic myeloid leukemia. Bone Marrow Transplant 1998; 21: 1079–1083.

    Article  CAS  PubMed  Google Scholar 

  11. Petersen FB, Buckner CD, Appelbaum FR et al. Busulfan, cyclophosphamide and fractionated total body irradiation as a preparatory regimen for marrow transplantation in patients with advanced hematological malignancies: a phase I study. Bone Marrow Transplant 1989; 4: 617–623.

    CAS  PubMed  Google Scholar 

  12. Przepiorka D, Ippoliti C, Giralt S et al. A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic marrow transplantation. Bone Marrow Transplant 1994; 14: 449–453.

    CAS  PubMed  Google Scholar 

  13. Rosales F, Naparstek E, Varadi G et al. The role of thiotepa in allogeneic stem cell transplantation in patients with leukemia. Leuk Res 1999; 23: 947–952.

    Article  CAS  PubMed  Google Scholar 

  14. Ratanatharathorn V, Karanes C, Lum LG et al. Allogeneic bone marrow transplantation in high-risk myeloid disorders using busulfan, cytosine arabinoside and cyclophosphamide (BAC). Bone Marrow Transplant 1992; 9: 49–55.

    CAS  PubMed  Google Scholar 

  15. Nagatoshi Y, Okamura J, Ikuno Y et al. Therapeutic trial of intensified conditioning regimen with high-dose cytosine arabinoside, cyclophosphamide and either total body irradiation or busulfan followed by allogeneic bone marrow transplantation for myelodysplastic syndrome in children. Int J Hematol 1997; 65: 269–275.

    Article  CAS  PubMed  Google Scholar 

  16. Carpenter PA, Marshall GM, Giri N et al. Allogeneic bone marrow transplantation for children with acute lymphoblastic leukemia conditioned with busulfan, cyclophosphamide and melphalan. Bone Marrow Transplant 1996; 18: 489–494.

    CAS  PubMed  Google Scholar 

  17. Zander AR, Culbert S, Jagannath S et al. High dose cyclophosphamide, BCNU, and VP-16 (CBV) as a conditioning regimen for allogeneic bone marrow transplantation for patients with acute leukemia. Cancer 1987; 59: 1083–1086.

    Article  CAS  PubMed  Google Scholar 

  18. Vaughan WP, Dennison JD, Reed EC et al. Improved results of allogeneic bone marrow transplantation for advanced hematologic malignancy using busulfan, cyclophosphamide and etoposide as cytoreductive and immunosuppressive therapy. Bone Marrow Transplant 1991; 8: 489–495.

    CAS  PubMed  Google Scholar 

  19. Kroger N, Zabelina T, Sonnenberg S et al. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia. Bone Marrow Transplant 2000; 26: 711–716.

    Article  CAS  PubMed  Google Scholar 

  20. von Bueltzingsloewen A, Belanger R, Perreault C et al. Allogeneic bone marrow transplantation following busulfan–cyclophosphamide with or without etoposide conditioning regimen for patients with acute lymphoblastic leukaemia. Br J Haematol 1993; 85: 706–713.

    Article  CAS  PubMed  Google Scholar 

  21. Zander AR, Berger C, Kroger N et al. High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission. Clin Cancer Res 1997; 3: 2671–2675.

    CAS  PubMed  Google Scholar 

  22. Stadtmauer EA, Cassileth PA, Gale RP . Etoposide in leukemia, lymphoma and bone marrow transplantation. Leuk Res 1989; 13: 639–650.

    Article  CAS  PubMed  Google Scholar 

  23. Bensinger WI, Buckner CD, Clift RA et al. Phase I study of busulfan and cyclophosphamide in preparation for allogeneic marrow transplant for patients with multiple myeloma. J Clin Oncol 1992; 10: 1492–1497.

    Article  CAS  PubMed  Google Scholar 

  24. Schiller G, Nimer S, Vescio R et al. Phase I-II study of busulfan and cyclophosphamide conditioning for transplantation in advanced multiple myeloma. Bone Marrow Transplant 1994; 14: 131–136.

    CAS  PubMed  Google Scholar 

  25. Copelan EA, Penza SL, Pohlman B et al. Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2000; 25: 1243–1248.

    Article  CAS  PubMed  Google Scholar 

  26. Bennett JM, Catovsky D, Daniel MT et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French–American–British Cooperative Group. Ann Intern Med 1985; 103: 620–625.

    Article  CAS  PubMed  Google Scholar 

  27. Vardiman JW, Harris NL, Brunning RD . The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292–2302.

    Article  CAS  PubMed  Google Scholar 

  28. Kaplan EL, Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.

    Article  Google Scholar 

  29. Gray RJ . A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141–1154.

    Article  Google Scholar 

  30. Fine JP, Gray RJ . A proportional hazards model for the subdistribution of a competing risk. JASA 1999; 94: 496–509.

    Article  Google Scholar 

  31. Gupta V, Lazarus HM, Keating A . Myeloablative conditioning regimens for AML allografts: 30 years later. Bone Marrow Transplant 2003; 32: 969–978.

    Article  CAS  PubMed  Google Scholar 

  32. Ljungman P, Hassan M, Bekassy AN et al. High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients. Bone Marrow Transplant 1997; 20: 909–913.

    Article  CAS  PubMed  Google Scholar 

  33. Dix SP, Wingard JR, Mullins RE et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996; 17: 225–230.

    CAS  PubMed  Google Scholar 

  34. Crilley P, Topolsky D, Styler MJ et al. Extramedullary toxicity of a conditioning regimen containing busulphan, cyclophosphamide and etoposide in 84 patients undergoing autologous and allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 15: 361–365.

    CAS  PubMed  Google Scholar 

  35. Spitzer TR, Cottler-Fox M, Torrisi J et al. Escalating doses of etoposide with cyclophosphamide and fractionated total body irradiation or busulfan as conditioning for bone marrow transplantation. Bone Marrow Transplant 1989; 4: 559–565.

    CAS  PubMed  Google Scholar 

  36. Jones RJ, Santos GW . New conditioning regimens for high risk marrow transplants. Bone Marrow Transplant 1989; 4 (Suppl. 4): 15–17.

    CAS  PubMed  Google Scholar 

  37. Spitzer TR, Peters C, Ortlieb M et al. Etoposide in combination with cyclophosphamide and total body irradiation or busulfan as conditioning for marrow transplantation in adults and children. Int J Radiat Oncol Biol Phys 1994; 29: 39–44.

    Article  CAS  PubMed  Google Scholar 

  38. Clark PI, Slevin ML . The clinical pharmacology of etoposide and teniposide. Clin Pharmacokinet 1987; 12: 223–252.

    Article  CAS  PubMed  Google Scholar 

  39. Kroger N, Hoffknecht M, Hanel M et al. Busulfan, cyclophosphamide and etoposide as high-dose conditioning therapy in patients with malignant lymphoma and prior dose-limiting radiation therapy. Bone Marrow Transplant 1998; 21: 1171–1175.

    Article  CAS  PubMed  Google Scholar 

  40. Przepiorka D, Dimopoulos M, Smith T et al. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for marrow transplantation: risk factors for early regimen-related toxicity. Ann Hematol 1994; 68: 183–188.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hematologic Malignancies Program, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA

    S S Farag, P J Elder, T Lin, S Penza, G Marcucci, W Blum, B R Avalos, J C Byrd & E Copelan

  2. Bone Marrow Transplantation Program, Cleveland Clinic Foundation, Cleveland, OH, USA

    B J Bolwell, M Kalaycio, B Pohlman & R Sobecks

Authors
  1. S S Farag
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B J Bolwell
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P J Elder
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Kalaycio
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. B Pohlman
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S Penza
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. G Marcucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. W Blum
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. R Sobecks
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. B R Avalos
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. J C Byrd
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. E Copelan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S S Farag.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Farag, S., Bolwell, B., Elder, P. et al. High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia. Bone Marrow Transplant 35, 653–661 (2005). https://doi.org/10.1038/sj.bmt.1704867

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704867

Keywords

This article is cited by

Search

Advanced search

Quick links